New treatment options for patients with resected stage III melanoma have been established with the publication of the results of four pivotal randomized clinical trials, resulting in three drug approvals, with a forth expected, all within only 4 years. Herein, we put these advances into context.
References
Ugurel, S. et al. Survival of patients with advanced metastatic melanoma: the impact of novel therapies-update 2017. Eur. J. Cancer 83, 247–257 (2017).
Eggermont, A. M. Prolonged survival with Ipilimumab as adjuvant in stage III melanoma. N. Engl. J. Med. 375, 1845–1855 (2016).
Weber, J. et al. Adjuvant nivolumab versus ipilimumab in resected stage III or IV melanoma. N. Engl. J. Med. 377, 1824–1835 (2017).
Long, G. V. et al. Adjuvant dabrafenib plus trametinib in stage III BRAF-mutated melanoma. N. Engl. J. Med. 377, 1813–1823 (2017).
Eggermont, A. M. et al. Adjuvant pembrolizumab versus placebo in resected stage III melanoma. N. Engl. J. Med. 378, 1789–1801 (2018).
Ives, N. J. et al. Adjuvant interferon-α for the treatment of high-risk melanoma: an individual patient data meta-analysis. Eur. J. Cancer 82, 171–183 (2017).
Leiter, U. et al. Complete lymph node dissection versus no dissection in patients with sentinel lymph node biopsy positive melanoma (DeCOG-SLT): a multicentre, randomised, phase 3 trial. Lancet Oncol. 17, 757–767 (2016).
Faries, M. B. et al. Completion dissection or observation for sentinel-node metastasis in melanoma. N. Engl. J. Med. 376, 2211–2222 (2017).
Verver, D. et al. Risk stratification of sentinel node-positive melanoma patients defines surgical management and adjuvant therapy treatment considerations. Eur. J. Cancer. 96, 25–33 (2018).
Amaria, R. N. et al. Neoadjuvant plus adjuvant dabrafenib and trametinib versus standard of care in patients with high-risk, surgically resectable melanoma: a single-centre, open-label, randomised, phase 2 trial. Lancet Oncol. 19, 181–193 (2018).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
A.M.M.E. has received consulting and/or advisory board fees from Actelion, Agenus, Bayer, Bristol-Myers Squibb (BMS), Ellipses, GlaxoSmithKline (GSK), HalioDX, Incyte, MedImmune, Merck, Sharp & Dohme (MSD), Merck-Serono, Nektar, Novartis, Pfizer, and Sanofi. C.R. has received consulting and/or advisory board fees from Amgen, BMS, GSK, Merck, Novartis, and Roche. A.R. has received consulting and/or advisory board fees from Amgen, BMS, Chugai, Genentech, Merck, Novartis, and Roche and is on the scientific advisory board of Arcus, BioncoTech, Compugen, CytomX, Five Prime, FLX-Bio, ImaginAb, Isoplexis, Lutris, Programme of Action for Cancer Therapy (PACT), Rgenix, and Tango.
Rights and permissions
About this article
Cite this article
Eggermont, A.M.M., Robert, C. & Ribas, A. The new era of adjuvant therapies for melanoma. Nat Rev Clin Oncol 15, 535–536 (2018). https://doi.org/10.1038/s41571-018-0048-5
Published:
Issue Date:
DOI: https://doi.org/10.1038/s41571-018-0048-5
- Springer Nature Limited
This article is cited by
-
Neurological toxicities of targeted therapies in melanoma: a multicenter national observational study of the French Group of Skin Cancers (Groupe de Cancérologie Cutanée, GCC)
Journal of Neurology (2024)
-
The role of mitochondria in the resistance of melanoma to PD-1 inhibitors
Journal of Translational Medicine (2023)
-
Molecular characteristics and therapeutic implications of Toll-like receptor signaling pathway in melanoma
Scientific Reports (2023)
-
The “Great Debate” at Melanoma Bridge 2021, December 2nd–4th, 2021
Journal of Translational Medicine (2022)
-
Impact of Circulating and Tissue Biomarkers in Adjuvant and Neoadjuvant Therapy for High-Risk Melanoma: Ready for Prime Time?
American Journal of Clinical Dermatology (2021)